JAK2 and rheumatoid arthritis: To the best of our knowledge, there are no available data about the effect of escitalopram on the STAT-3/JAK-2 signaling pathway in patients with RA, and there are still considerable gaps in understanding the mechanistic characterization of the immunomodulatory effects of escitalopram.